Menta "Steve" Wallace packed his pills on ice and boarded a Caribbean cruise last month—a journey he and his wife Jo Linda thought pancreatic cancer had stolen from them. The 74-year-old from Houston was diagnosed in January, but after just a few months on an experimental drug called daraxonrasib, his tumor shrank by 46% and he got his life back enough to travel again.
Wallace's story is no isolated victory. Results from a 500-person trial unveiled this week at the American Society of Clinical Oncology meeting in Chicago show that Revolution Medicine's daraxonrasib doubled survival in advanced pancreatic cancer patients compared with standard chemotherapy—a breakthrough researchers are calling unprecedented in this deadly disease. The drug reduced overall risk of death by 60% and helped nearly a third of patients halt or reverse tumor progression, compared with just 10% on chemotherapy alone.
Pancreatic cancer has long been a grim diagnosis. It carries the highest mortality rate of any major cancer, with roughly 68,000 Americans diagnosed annually and 53,000 dying from it. Only 3% of patients whose cancer has spread to distant organs survive five years, and about 80% are already at advanced stages when caught. Against this backdrop, the trial results represent a genuine shift in what's possible for patients who have exhausted their first round of chemotherapy.
The key innovation is that daraxonrasib targets RAS mutations—variants of a gene that drives cancer growth and appears in up to 90% of pancreatic cancers. In patients with a specific RAS variant called G12, tumors remained controlled for a median of 7.3 months on daraxonrasib versus 3.5 months with chemotherapy. Among this group, 33.2% saw their cancers shrink or disappear, compared with 11.8% on chemotherapy. The drug takes the form of a once-daily pill, offering patients a less burdensome treatment schedule than traditional chemotherapy.
The survival advantage was stark in the overall trial population: patients on daraxonrasib lived a median of 13.2 months from diagnosis versus 6.7 months for those on standard chemotherapy. Dr. Brian Wolpin of Harvard's Dana-Farber Cancer Institute, who led the trial, said the results "will change how scientists, clinicians, and patients think about treatment for pancreatic cancer."
The drug does come with side effects. Rash affected 86.3% of patients, along with nausea, diarrhea, and mouth inflammation. But Wolpin emphasized these are largely manageable with antibiotics and topical steroids, and importantly, only 1.2% of patients discontinued treatment due to adverse events. Severe or life-threatening side effects were actually less common in the daraxonrasib group (43.6%) than in those receiving chemotherapy (57.5%).
Revolution Medicine is already testing daraxonrasib in earlier-stage disease and in combination with other treatments, hoping to extend its benefits even further. For patients like Wallace, the drug has already delivered something priceless: the chance to reclaim stolen time. He's traveling the world with his wife, his tumor in check, proving that even for cancers as aggressive as pancreatic cancer, the trajectory of hope can shift with the right medicine.